Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1091126

registered interest
date	19/03/2019
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Public Interest Disclosure Act 1998
house id	1
legislature	25259 pref label House of Commons
question text	What plans he has to review the operation of the Public Interest Disclosure Act 1998.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	909885
answer	answer is ministerial correction date of answer 19/03/2019 answer text <p>The Government has continued to examine and make reforms to the whistleblowing regime, both to the guidance and legislative framework of protections for workers. The most recent reforms came into effect last year.</p><p> </p><p>The Government will continue to listen to stakeholders and will, of course, review the recent reforms once there is sufficient evidence of their impact.</p> answering member constituency Rochester and Strood answering member printed Kelly Tolhurst question first answered 19/03/2019 15:16:28 answering member 4487 label Biography information for Kelly Tolhurst
tabling member	4385 label Biography information for Dr Philippa Whitford

1082133

registered interest
date	05/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antimicrobials: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Tackling Antimicrobial Resistance Action Plan 2019-2024, how delinking the price paid for antimicrobials from the volume sold will ensure that products produced by industry are affordable to the NHS.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	228682
answer	answer is ministerial correction date of answer 11/03/2019 answer text <p>The 2016 United Nations political declaration on antimicrobial resistance (AMR) acknowledged the importance of delinking the cost of investment in research and development on AMR from the price and volume of sales to facilitate equitable and affordable access to new products and encouraged governments to explore innovative approaches.</p><p> </p><p>It is critical that the National Health Service makes the best use of its resources. Any payment model must therefore be based on a robust evaluation of the value that a new antimicrobial product brings to patients and the public as a whole. The assessment of how much value a new antibiotic brings is highly complex and will vary considerably from one product to another.</p><p> </p><p>In the United Kingdom, NHS England and the National Institute for Health and Care Excellence (NICE) are leading work to test innovative models that pay companies based primarily on a NICE led health technology assessment of their value to the NHS as opposed to the volumes used. This has the potential to both promote good antimicrobial stewardship and provide a much-needed incentive for the development of new antimicrobial agents that will, over time, provide value for the NHS.</p><p> </p><p>The test will be subject to robust evaluation before considering any wider change to purchasing policy. The UK represents only a small part of the global market for these drugs and we want to send a signal to the rest of the world that there are workable models to achieve the right sort of incentives for these vital medicines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 228683 question first answered 11/03/2019 18:32:38 answering member 4067 label Biography information for Steve Brine previous answer version 106924 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

1082134

registered interest
date	05/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antimicrobials: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of using models that de-link the cost of research and development from the price of the final product and the volume of sales, as set out in the 2016 UN Political Declaration of the High-Level Meeting of the General Assembly on antimicrobial resistance, to ensure that new diagnostics, medicines and tools created are accessible and affordable.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	228683
answer	answer is ministerial correction date of answer 11/03/2019 answer text <p>The 2016 United Nations political declaration on antimicrobial resistance (AMR) acknowledged the importance of delinking the cost of investment in research and development on AMR from the price and volume of sales to facilitate equitable and affordable access to new products and encouraged governments to explore innovative approaches.</p><p> </p><p>It is critical that the National Health Service makes the best use of its resources. Any payment model must therefore be based on a robust evaluation of the value that a new antimicrobial product brings to patients and the public as a whole. The assessment of how much value a new antibiotic brings is highly complex and will vary considerably from one product to another.</p><p> </p><p>In the United Kingdom, NHS England and the National Institute for Health and Care Excellence (NICE) are leading work to test innovative models that pay companies based primarily on a NICE led health technology assessment of their value to the NHS as opposed to the volumes used. This has the potential to both promote good antimicrobial stewardship and provide a much-needed incentive for the development of new antimicrobial agents that will, over time, provide value for the NHS.</p><p> </p><p>The test will be subject to robust evaluation before considering any wider change to purchasing policy. The UK represents only a small part of the global market for these drugs and we want to send a signal to the rest of the world that there are workable models to achieve the right sort of incentives for these vital medicines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 228682 question first answered 11/03/2019 18:32:38 answering member 4067 label Biography information for Steve Brine previous answer version 106925 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

1077138

registered interest
date	25/02/2019
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Breast Cancer: Mortality Rates
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Minister for the Cabinet Office, if he will publish data on the under 75 directly age-standardised breast cancer mortality rates in women per 100,000 (European Standard Population) by Clinical Commissioning Group in (a) 2012-14, (b) 2013-15, (c) 2014-16 and (d) 2015-17.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	225534
answer	answer is ministerial correction date of answer 28/02/2019 answer text <p>The information requested falls within the responsibility of the UK Statistics Authority. The information will be placed in the Library once provided by the UKSA.</p> answering member constituency Norwich North answering member printed Chloe Smith question first answered 28/02/2019 10:33:08 answering member 1609 label Biography information for Chloe Smith attachment 1 file name Combined PQ225534, 225535 (1).pdf title UKSA Response
tabling member	4385 label Biography information for Dr Philippa Whitford

1077139

registered interest
date	25/02/2019
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Breast Cancer: Death
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Minister for the Cabinet Office, how many women aged under 75 years died from breast cancer, by CCG, in (a) 2012-14, (b) 2013-15, (c) 2014-16 and (d) 2015-17.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	225535
answer	answer is ministerial correction date of answer 28/02/2019 answer text <p>The information requested falls within the responsibility of the UK Statistics Authority. The information will be placed in the Library once provided by the UKSA.</p> answering member constituency Norwich North answering member printed Chloe Smith question first answered 28/02/2019 10:33:25 answering member 1609 label Biography information for Chloe Smith attachment 1 file name Combined PQ225534, 225535 (1).pdf title UKSA Response
tabling member	4385 label Biography information for Dr Philippa Whitford